Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02161185 · ClinicalTrials.gov registry record · Phase 3
A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters
A Phase 3 study, sponsored by UCB Biopharma S.P.R.L..
- Terminated
- Registry status
- Phase 3
- Development phase
- 7
- Enrollment target
NCT02161185 is a Phase 3 study that was terminated before completion, run by UCB Biopharma S.P.R.L.. The registered enrollment target is 7 participants.
The verdict
NCT02161185, a Phase 3 study, was terminated before completion, sponsored by UCB Biopharma S.P.R.L..
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the long-term safety and tolerability of USL261 in the treatment of seizure clusters.
Interventions
- DRUG USL261
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2014-05 |
| Est. Completion | 2015-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02161185
The ClinicalTrials.gov registry entry for NCT02161185 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biopharma S.P.R.L., which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which USL261 is the first listed.
NCT02161185 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02161185 about?
NCT02161185 is a clinical study titled "A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters". The purpose of this study is to examine the long-term safety and tolerability of USL261 in the treatment of seizure clusters.
What is the current status of trial NCT02161185?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 7 participants. The study started on 2014-05. Estimated completion is 2015-05.
What interventions are being tested in trial NCT02161185?
The interventions under investigation include: USL261 (DRUG).
Who is sponsoring clinical trial NCT02161185?
This trial is sponsored by UCB Biopharma S.P.R.L., which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.